Jeremy R. Graff
CIK: 0001975028
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Sep 30, 2026ALLR
Allarity Therapeutics, Inc.
Tax Payment(F)Direct14.6K shares at avg. $0.97$14K - Sep 30, 2026ALLR
Allarity Therapeutics, Inc.
Exercise(M)Direct39.5K shares- - May 9, 2026INAB
IN8BIO, INC.
Award(A)DirectStock Option (right to buy)
22K shares- - Jan 28, 2026ALLR
Allarity Therapeutics, Inc.
Award(A)Direct133.3K shares- - Jan 22, 2026ALLR
Allarity Therapeutics, Inc.
Exercise(M)Direct48.1K shares- - Jan 22, 2026ALLR
Allarity Therapeutics, Inc.
Tax Payment(F)Direct17.8K shares at avg. $1.18$21K - Jan 7, 2026ALLR
Allarity Therapeutics, Inc.
Award(A)Direct133.3K shares- - Sep 30, 2025ALLR
Allarity Therapeutics, Inc.
Exercise(M)Direct39.5K shares- - Sep 30, 2025ALLR
Allarity Therapeutics, Inc.
Tax Payment(F)Direct14.6K shares at avg. $1.58$23K - May 8, 2025INAB
IN8BIO, INC.
Award(A)DirectStock Option (right to buy)
63.2K shares- - Apr 27, 2025INAB
IN8BIO, INC.
Award(A)DirectSeries B Warrants (right to buy)
2K shares- - Apr 27, 2025INAB
IN8BIO, INC.
Disposition(D)DirectSeries B Warrants (right to buy)
2K shares- - Jan 22, 2025ALLR
Allarity Therapeutics, Inc.
Award(A)Direct144.4K shares- - Dec 19, 2024INAB
IN8BIO, INC.
Award(A)DirectStock Option (right to buy)
47.7K shares- - Sep 30, 2024ALLR
Allarity Therapeutics, Inc.
Award(A)Direct118.5K shares at avg. $2.11$250K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 30, 2026 | ALLR Allarity Therapeutics, Inc. | Tax Payment(F) | 14,613 | $0.97 | $14,175 | Direct |
| Sep 30, 2026 | ALLR Allarity Therapeutics, Inc. | Exercise(M) | 39,494 | - | $0 | Direct |
| May 9, 2026 | INAB IN8BIO, INC. | Award(A) Stock Option (right to buy) | 22,000 | - | - | Direct |
| Jan 28, 2026 | ALLR Allarity Therapeutics, Inc. | Award(A) | 133,333 | - | $0 | Direct |
| Jan 22, 2026 | ALLR Allarity Therapeutics, Inc. | Exercise(M) | 48,147 | - | $0 | Direct |
| Jan 22, 2026 | ALLR Allarity Therapeutics, Inc. | Tax Payment(F) | 17,814 | $1.18 | $21,021 | Direct |
| Jan 7, 2026 | ALLR Allarity Therapeutics, Inc. | Award(A) | 133,333 | - | $0 | Direct |
| Sep 30, 2025 | ALLR Allarity Therapeutics, Inc. | Exercise(M) | 39,494 | - | - | Direct |
| Sep 30, 2025 | ALLR Allarity Therapeutics, Inc. | Tax Payment(F) | 14,613 | $1.58 | $23,089 | Direct |
| May 8, 2025 | INAB IN8BIO, INC. | Award(A) Stock Option (right to buy) | 63,150 | - | - | Direct |
| Apr 27, 2025 | INAB IN8BIO, INC. | Award(A) Series B Warrants (right to buy) | 2,049 | - | - | Direct |
| Apr 27, 2025 | INAB IN8BIO, INC. | Disposition(D) Series B Warrants (right to buy) | 2,049 | - | - | Direct |
| Jan 22, 2025 | ALLR Allarity Therapeutics, Inc. | Award(A) | 144,441 | - | $0 | Direct |
| Dec 19, 2024 | INAB IN8BIO, INC. | Award(A) Stock Option (right to buy) | 47,697 | - | - | Direct |
| Sep 30, 2024 | ALLR Allarity Therapeutics, Inc. | Award(A) | 118,483 | $2.11 | $249,999 | Direct |
1-15 of 15 transactions
About Graff Jeremy R.
Graff Jeremy R. (SEC CIK 0001975028) files insider reports with the SEC as Officer of Allarity Therapeutics, Inc. (ALLR) and Director of IN8BIO, INC. (INAB).
Signal8 holds 11 ownership filings by Graff Jeremy R. (1 Form 3, 10 Form 4), filed between Oct 1, 2024 and Oct 9, 2026. Those filings report 15 transactions, from Sep 30, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Graff Jeremy R.'s filings is in TARPON SPRINGS, FL.
Recent filings by Graff Jeremy R.
- Sep 30, 2026: Tax withholding of ALLR shares (Form 4, code F).
- Sep 30, 2026: Option exercise of ALLR shares (Form 4, code M).
- May 9, 2026: Grant or award of INAB derivative securities (Form 4, code A).
- Jan 28, 2026: Grant or award of ALLR shares (Form 4, code A).
- Jan 22, 2026: Option exercise of ALLR shares (Form 4, code M).
Other insiders filing for Allarity Therapeutics, Inc. (ALLR)
- Jensen Thomas, CEO
- Hoeiland Jesper, Director
- McLaughlin Gerald W., Director
- Ervin Jeffrey S, CFO
- Vazzano Joseph Walter, Director
- Benjamin Laura, Director